Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Raffaele Pezzilli

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9827-7451; OpenAlex author ID A5048017669. Sources: OpenAlex.

Their work

Papers
57 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
157
Papers, trials and grants by year

2011: 4 papers · 2012: 4 papers · 2013: 4 papers · 2014: 1 paper · 2015: 3 papers · 2016: 8 papers · 2017: 2 papers · 2018: 3 papers · 2019: 4 papers · 2020: 3 papers · 2021: 9 papers · 2022: 1 paper · 2023: 6 papers · 2024: 3 papers · 2025: 2 papers

Papers 50 of 57

  1. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional… Co-author DOI 10.1002/ijc.35196↗
  2. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/mutage/geae012↗
  3. Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk. Co-author DOI 10.1002/ijc.35046↗
  4. Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk. Co-author DOI 10.1186/s40246-024-00576-x↗
  5. Outcomes of a 3-Year Prospective Surveillance in Individuals at High Risk of Pancreatic Cancer. Co-author DOI 10.14309/ajg.0000000000002546↗
  6. Association between a polymorphic variant in the CDKN2B-AS1/ANRIL gene and pancreatic cancer risk. Co-author DOI 10.1002/ijc.34383↗
  7. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  8. Genetic and non-genetic risk factors for early-onset pancreatic cancer. Co-author DOI 10.1016/j.dld.2023.02.023↗
  9. A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarc… Co-author DOI 10.1093/carcin/bgad056↗
  10. Polymorphic variants involved in methylation regulation: a strategy to discover risk loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jmg-2022-108910↗
  11. Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians. Co-author DOI 10.1186/s40659-023-00457-y↗
  12. Common variability in oestrogen-related genes and pancreatic ductal adenocarcinoma risk in women. Co-author DOI 10.1038/s41598-022-22973-9↗
  13. Genome-wide scan of long noncoding RNA single nucleotide polymorphisms and pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.33475↗
  14. Pancreatic cancer in patients with autoimmune pancreatitis: A scoping review. Co-author DOI 10.1016/j.pan.2021.03.007↗
  15. Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival. Co-author DOI 10.1038/s41598-021-87130-0↗
  16. Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/carcin/bgab057↗
  17. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. Co-author DOI 10.1136/jmedgenet-2020-106961↗
  18. Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-21-0353↗
  19. [Screening protocols for pancreatic cancer.] Co-author DOI 10.1701/3525.35125↗
  20. Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Co-author DOI 10.3389/fgene.2021.693933↗
  21. Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. Co-author DOI 10.3389/fonc.2021.771312↗
  22. Genome-wide association study identifies an early onset pancreatic cancer risk locus. Co-author DOI 10.1002/ijc.33004↗
  23. Pancreatic Enzyme Replacement Therapy in Pancreatic Cancer. Co-author DOI 10.3390/cancers12020275↗
  24. Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by th… Co-author DOI 10.3390/cancers12061681↗
  25. Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study. Co-author DOI 10.1002/ijc.31928↗
  26. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.32127↗
  27. Results of First-Round of Surveillance in Individuals at High-Risk of Pancreatic Cancer from the AISP (Italian Association for the Study of the Pancreas) Regis… Co-author DOI 10.1038/s41395-018-0414-z↗
  28. Genetic variability of the ABCC2 gene and clinical outcomes in pancreatic cancer patients. Co-author DOI 10.1093/carcin/bgz006↗
  29. Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation. Co-author DOI 10.1002/ijc.31047↗
  30. Identification of Small Proteins and Peptides in the Differentiation of Patients with Intraductal Mucinous Neoplasms of the Pancreas, Chronic Pancreatitis and … First author DOI 10.1007/s10620-018-4944-4↗
  31. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Co-author DOI 10.1038/s41467-018-02942-5↗
  32. SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. Co-author DOI 10.1038/srep43812↗
  33. Serum endocannabinoids in assessing pain in patients with chronic pancreatitis and in those with pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/00365521.2017.1342139↗
  34. Overuse of surgery in patients with pancreatic cancer. A nationwide analysis in Italy. Last author DOI 10.1016/j.hpb.2015.11.005↗
  35. A comprehensive analysis on expected years of life lost due to pancreatic cancer. Co-author DOI 10.1016/j.pan.2016.02.005↗
  36. Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1093/carcin/bgw080↗
  37. Estimation of the Survival Benefit Obtainable From Screening for the Early Detection of Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000523↗
  38. Can Serum Pancreatic Amylase and Lipase Levels Be Used as Diagnostic Markers to Distinguish Between Patients With Mucinous Cystic Lesions of the Pancreas, Chro… Co-author DOI 10.1097/mpa.0000000000000638↗
  39. Implications and issues related to familial pancreatic cancer: a cohort study of hospitalized patients. Last author DOI 10.1186/s12876-016-0421-8↗
  40. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Co-author DOI 10.18632/oncotarget.10935↗
  41. Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. Co-author DOI 10.18632/oncotarget.11041↗
  42. TERT gene harbors multiple variants associated with pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.29590↗
  43. Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Co-author DOI 10.1038/ng.3341↗
  44. Markers of Bone Metabolism in Patients With Chronic Pancreatitis and Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/md.0000000000001754↗
  45. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Co-author DOI 10.1038/ng.3052↗
  46. Genetic susceptibility to pancreatic cancer and its functional characterisation: the PANcreatic Disease ReseArch (PANDoRA) consortium. Co-author DOI 10.1016/j.dld.2012.09.014↗
  47. Lack of replication of seven pancreatic cancer susceptibility loci identified in two Asian populations. Co-author DOI 10.1158/1055-9965.epi-12-1182↗
  48. Is diabetes mellitus a risk factor for pancreatic cancer? Co-author DOI 10.3748/wjg.v19.i30.4861↗
  49. ABO blood groups and pancreatic cancer risk and survival: results from the PANcreatic Disease ReseArch (PANDoRA) consortium. Co-author DOI 10.3892/or.2013.2285↗
  50. Expression of the antiapoptotic protein BAG3 is a feature of pancreatic adenocarcinoma and its overexpression is associated with poorer survival. Co-author DOI 10.1016/j.ajpath.2012.07.016↗

Closest collaborators

The 25 strongest of 157 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gabriele Capurso · 12 shared papers, 2013–2024 · strength 0.86
  2. Giulia Martina Cavestro · 6 shared papers, 2019–2024 · strength 0.56
  3. Federico Canzian · 9 shared papers, 2013–2023 · strength 0.52
  4. Daniele Campa · 9 shared papers, 2013–2023 · strength 0.52
  5. Pavel Souček · 9 shared papers, 2013–2023 · strength 0.52
  6. Francesca Tavano · 8 shared papers, 2012–2023 · strength 0.49
  7. John P. Neoptolemos · 7 shared papers, 2013–2023 · strength 0.44
  8. Beatrice Mohelníková-Duchoňová · 7 shared papers, 2013–2023 · strength 0.43
  9. Renata Talar‐Wojnarowska · 8 shared papers, 2013–2022 · strength 0.41
  10. Pavel Vodička · 7 shared papers, 2013–2023 · strength 0.38
  11. Alessandra Barassi · 4 shared papers, 2015–2018 · strength 0.37
  12. Manuel Gentiluomo · 4 shared papers, 2019–2023 · strength 0.36
  13. Thilo Hackert · 5 shared papers, 2016–2023 · strength 0.35
  14. Massimo Falconi · 3 shared papers, 2019–2024 · strength 0.34
  15. Lívia Archibugi · 3 shared papers, 2022–2024 · strength 0.33
  16. Rita Teresa Lawlor · 4 shared papers, 2017–2023 · strength 0.32
  17. Maria Gazouli · 6 shared papers, 2013–2022 · strength 0.31
  18. Silvia Carrara · 3 shared papers, 2019–2024 · strength 0.31
  19. Giuseppe Vanella · 3 shared papers, 2021–2023 · strength 0.29
  20. Casper H.J. van Eijck · 3 shared papers, 2021–2023 · strength 0.29
  21. Giovanni Butturini · 3 shared papers, 2016–2024 · strength 0.24
  22. Oliver Strobel · 4 shared papers, 2016–2021 · strength 0.24
  23. Marta Puzzono · 2 shared papers, 2023–2024 · strength 0.24
  24. Oronzo Brunetti · 2 shared papers, 2020 · strength 0.23
  25. Michèle Milella · 2 shared papers, 2020 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.